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Abstract
Severe spinal cord injury (SCI) leads to devastating neurological deficits and disabilities, which
necessitates spending a great deal of health budget for psychological and healthcare problems of
these patients and their relatives. This justifies the cost of research into the new modalities for
treatment of spinal cord injuries, even in developing countries. Apart from surgical management
and nerve grafting, several other approaches have been adopted for management of this condition
including pharmacologic and gene therapy, cell therapy, and use of different cell-free or cell-seeded
bioscaffolds. In current paper, the recent developments for therapeutic delivery of stem and non-
stem cells to the site of injury, and application of cell-free and cell-seeded natural and synthetic
scaffolds have been reviewed.
Introduction
Spinal cord injury (SCI) usually leads to devastating neu-
rological deficits and disabilities. The data published by
the National Spinal Cord Injury Statistical Center in 2005
[1] showed that the annual incidence of SCI in the United
States is estimated to be 40/milliion. It also estimated that
the number of patients with SCI in US was estimated to be
225,000 to 288,000 persons in July 2005 (see Ackery et al
[2] for a review on the worldwide epidemiology of SCI).
It has been shown that patients with SCI have more
depressive feelings than general population [3]. The mar-
riage of patients who are married at the time of injury is
more likely to be compromised than general population.
Also, the likelihood of getting married after the injury is
lower than the general population [1]. In addition, there
are significant reductions in rates of occupation and
employment after injury, especially during the first year
[4].
In addition, tremendous costs are imposed on commu-
nity by the spinal cord injury. The costs include cost of ini-
tial and subsequent hospitalizations, rehabilitation and
supportive equipment, home modifications, personal
assistance, institutional care and loss of income. It has
been shown that the average initial hospital expenses for
a patient with SCI is around $95000 and the average
yearly expenses after recovery and rehabilitation is around
$14135 [5]. The average lifetime cost that is directly attrib-
uted to SCI is estimated to be $620000–$2800000 for
each patient aged 25 years at the time of injury, and
$450000–1600000 for each patient aged 50 at the time of
injury [1].
These data show that apart from the patients, SCI imposes
high psychosocial and financial costs to the family of the
patient and to the community. Therefore, investment for
the development of any treatment modality that improves
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ishes the health care costs of SCI is quite justifiable.
Pathophysiology
The neurological damage that is incurred at the time of
mechanical trauma to the spinal cord is called "primary
injury". The primary injury provokes a cascade of cellular
and biochemical reactions that leads to further damage.
This provoked cascade of reactions is called "secondary
injury".
Primary injury occurs following (1) blunt impact, (2)
compression, and (3) penetrating trauma. Blunt impacts
can lead to concussion, contusion, laceration, transection
or intraparenchymal hemorrhage. Cord compression usu-
ally results from hyperflexion, hyperextension, axial load-
ing, and severe rotation [6]. Gunshot and stab wounds are
examples of penetrating traumas. The immediate
mechanical damage to the neurons leads to the cell necro-
sis at the point of impact [7].
Several mechanisms are involved in secondary injury of
which, vascular changes at the site of injury are the most
important events. The microvascular alterations include
loss of autoregulation, vasospasm, thrombosis, hemor-
rhage and increased permeability. These, in combination
with edema, lead to hypoperfusion, ischemia and necrosis
[8]. Other major mechanisms include: (1) free radicals
formation and lipid peroxidation [9] (2) accumulation of
excitatory neurotransmitters, e.g. glutamate (acting on N-
methyl-D-aspartate [NMDA] and non-NMDA receptors),
and neural damage due to excessive excitation (excitotox-
icity) [10] (3) loss of intracellular balance of sodium,
potassium, calcium and magnesium and subsequent
increased intracellular calcium level [11] (4) increased
level of opioids, especially dynorphins, at the site of
injury, which contribute to the pathophysiology of sec-
ondary injury [12,13] (5) depletion of energy metabolites
leading to anaerobic metabolism at the site of injury and
increasing of LDH activity [14] (6) provocation of an
inflammatory response and recruitment and activation of
inflammatory cells associated with secretion of cytokines,
which contribute to further tissue damage [15], and (7)
activation of calpains [16] and caspases and apoptosis
[17,18].
Primary and secondary injuries lead to the cell loss in the
spinal cord. In penetrating injuries, this leads to scarring
and tethering of the cord [7]. Demyelination occurs fol-
lowing the loss of oligodendrocytes, which causes con-
duction deficits [19]. In contusion injuries, a cystic cavity
surrounded by an astrocytic scar is formed following this
tissue loss. Where the injury extends to pia mater, collagen
will also contribute in the formation of the scar tissue. As
a physical barrier, the scar dos not allow the axons to grow
across the cavity [20].
Crushed or transected nerve fibers exhibit regenerative
activities by outgrowth of neurites. This is called regener-
ative sprouting. But, this would not be more than 1 mm,
because there are inhibitory proteins in the CNS that
inhibit this activity [21]. Among these inhibitory proteins,
the myelin proteins Nogo and MAG could be named,
which are exposed after the injury [22,23]. Inhibitory pro-
teins have been identified in the extracellular matrix of the
scar tissue as well, mainly chondroitin sulfate proteogly-
cans (CSPGs) secreted by reactive astrocytes [7,24]. Per-
manent hyperexcitability is another mechanism that
develops in many cells leading to different signs and
symptoms [7].
Approaches to treatment
Stabilization of the spine and restoration of its normal
alignment together with surgical decompression of the
cord is the subject of individual or institutional prefer-
ences; and there is no consensus regarding necessity, tim-
ing, nature, or approach of surgical intervention [25,26].
There have been several attempts to target and modulate
the mechanisms leading to the secondary injury by phar-
macological interventions (see Sayer et al [27] and Bap-
tiste and Fehlings [28] for review), neutralization of the
effects of regenerative sprouting inhibitory proteins (see
Scott et al [29] for review) and gene therapy (see Blits and
Bunge [30] and Pearse and Bunge [31] for review).
The core approach of tissue engineering consists of provi-
sion of an interactive environment between cells, scaf-
folds and bioactive molecules to promote tissue repair. To
achieve this goal, the ex vivo engineered cell-scaffold con-
structs could be transplanted to the site of injury. Alterna-
tively, the repair is achieved by delivery of scaffold-free
cells or acellular scaffolds to the damaged tissue.
Cell therapy
Macrophages
Due to the immune privilege, recruitment of macrophages
is limited in CNS and the resident microglia cells are the
main immune cells that are activated after SCI [19]. It has
been shown that controlled boosting of local immune
response by delivering of autologous macrophages, which
were alternatively activated to a wound-healing pheno-
type, can promote recovery from the spinal cord injury.
Initial experiments with implantation of macrophages
activated by preincubation with peripheral nerve frag-
ments lead to partial recovery of paraplegic rats [32].
Improved motor recovery and reduced spinal cyst forma-
tion of rats was also observed by implantation of macro-
phages activated by incubation with autologous skin [33].Page 2 of 16
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cells, and increased production of trophic factors such as
brain-derived neurotrophic factor (BDNF) [33,34] lead-
ing to removal of inhibitory myelin debris [32]. Promo-
tion of a permissive extracellular matrix containing
laminin is another observation [34]. Following these and
subsequent positive results from animal experiments,
autologous macrophages activated by incubation with
autologous skin, under the brand name of ProCord, were
entered into a multicentric clinical trial. The results of
phase I studies show that out of eight patients in the study,
three recovered clinically significant neurological motor
and sensory function. Also, it has been shown that this
cell therapy is well tolerated in patients with acute SCI
[35].
Dendritic cells
In animal model studies, transplantation of dendritic cells
into the injured spinal cord of mice led to better func-
tional recovery as compared to controls [36]. The
implanted dendritic cells induced proliferation of endog-
enous neural stem/progenitor cells (NSPCs) and led to de
novo neurogenesis. This observation was attributed to the
action of secreted neurotrophic factors such as neuro-
trophin-3, cell-attached plasma membrane molecules,
and possible activation of microglia/macrophages by
implanted dendritic cells [36].
Dendritic cells pulsed (incubated) with encephalitogenic
or non-encephalitogenic peptides derived from myelin
basic protein when administered intravenously or locally
to the site of injury, promoted recovery from SCI [37]. The
mechanisms proposed to explain this phenomenon is
based on presentation of the loaded antigen to the naïve
T cells by dendritic cells. The stimulated T cells start a cas-
cade of events leading to "beneficial autoimmunity". They
may secrete growth factors that protect the injured tissue.
Also, they lead to a transient reduction in the nerve's elec-
trophysiological activities, decreasing nerve's metabolic
requirements and thus preserving neuronal viability [38].
This explanation is in line with the finding that in those
rats, which are unresponsive to myelin self-antigens, the
outcome of CNS injury is worse than normal rats [39].
Olfactory ensheathing cells (OECs)
Olfactory ensheathing cells (OECs) are glial cells
ensheathing the axons of the olfactory receptor neurons.
These cells have properties of both Schwann cells and
astrocytes, with a phenotype closer to the Schwann cells
[40]. OECs can be obtained from olfactory bulb or nasal
mucosa (lamina propria). Cells from both sources have
been used for treatment of spinal cord injury in animal
models. Those from olfactory bulb origin lead to axonal
regeneration and functional recovery after transplantation
to animals with transected [41,42], hemisected [43,44] or
contused [45] spinal cords. Similar results were also
obtained by transplantation of OECs isolated from lam-
ina propris in both transected [46] and hemisected [47]
models. It has been shown that these cells are able to
retain their regenerative ability after cryopreservation [48]
and after establishment of a clonally derived cell line [49].
Boosting of regenerative capability of OECs by overex-
pression of brain-derived neurotrophic factor (BDNF)
[50] or glial cell line-derived neurotrophic factor (GDNF)
[51] was also tried successfully in animal models.
OECs migrate after implantation [52], decrease neuronal
apoptosis [53] and secrete a number of extracellular
matrix molecules such as type IV collagen, and the chon-
droitin sulfate proteoglycan NG2 [54]. They also secrete
trophic factors such as vascular endothelial growth factor
(VEGF) [54], nerve growth factor (NGF), and BDNF [55].
Remyelination is also increased after transplantation of
OECs [56-58]. A comparison of acute versus delayed
transplantation of OECs has shown that acute transplan-
tation leads to earlier recovery and better functional and
histological results [59]. The efficacy and behavior of
olfactory bulb-derived cells were compared with lamina
propria (LP)-derived cells after implantation. LP-derived
cells showed superior ability to migrate within the spinal
cord, and reduce the cavity formation and lesion size, but
they enhanced autotomy [60]. All the above properties
can explain the observed histological and functional
improvements following transplantation of olfactory
ensheathing cells to the site of injury.
According to the promising results obtained from animal
experiments, several clinical trials have been started. In a
large series more than 400 patients underwent transplan-
tation of fetal olfactory bulb-derived cells, of which the
results of 171 operations were published [61], showing
functional recovery, regardless of age and as early as the
first day after implantation [61]. But, an independent
observational study of 7 cases from this series did not
report any clinically useful sensorimotor, disability, or
autonomic improvements [62]. In a recent case report, a
rapid functional recovery was noted within 48 hours of
transplantation of olfactory bulb-derived cells [63]. This
reemphasizes the need for further studies into the mecha-
nism of action of these cells, as according to the animal
studies, such a rapid start of improvement is not expected.
Nasal mucosal-derived OECs were also used in a phase I
clinical trial conducted on 3 patients who were followed
for one year after transplantation [64]. The results confirm
the safety and feasibility of this approach.
Schwann cells (SCs)
Schwann cells originating from dorsal and ventral roots
are one of the cellular components that migrate to the site
of tissue damage after spinal cord injury [65-68]. ThePage 3 of 16
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onstrated in a number of studies [66,69] and the function-
ing status of this myelin in conduction of neural impulses
was confirmed [70,71]. SCs promote axonal regeneration
by secretion of adhesion molecules such as L1 and N-
CAM, extracellular matrix molecules such as collagen [72]
and laminin (see Chernousov and Carey [73] for review),
and a number of trophic factors such as FGF-2 [74], nerve
growth factor (NGF), brain-derived neurotrophic factor
(BDNF) and NT3 (see Mirsky et al [75] for review). In
addition to their on neural regeneration and remyelina-
tion, a number of unwanted effects were also reported fol-
lowing the use of these cells. It has been shown that when
SCs come into contact with CNS astrocytes, their migra-
tion into the CNS is stopped [76]. Also, corticospinal
tracts (CST) show a delayed and poor regenerative activity
in response to Schwann cells implantation when com-
pared with OECs [77]. The other unwanted issue in regard
to SCs is that the damaged axons, which are stimulated by
these cells to regenerate, grow into the grafted population
of Schwann cells, but there is little evidence to support
that they leave these cells and re-enter their original white
matter pathways [70]. When combining SCs transplanta-
tion with delivering of neurotrophic factors [78] or OECs
plus chondroitinase [79] exit of regenerating axons could
be observed from the transplanted population of grafted
cells.
In animal model studies, Schwann cells are isolated from
either newborn or adult sciatic nerve and cultured in the
presence of mitogens. Upon transplantation to the dam-
aged spinal cord of adult animals, they stimulate tissue
repair by causing regenerating axons and astroglia to
express developmentally related molecules. When com-
pared with the effects of OECs in an acute SCI setting, it
was concluded that the degree of functional recovery
achieved by SCs is less than OECs [80]. It has been shown
that delayed transplantation leads to a higher survival of
SCs in host tissue as compared with acute transplantation;
meanwhile, implanted Schwann cells cause extensive
infiltration of endogenous SCs to the site of injury [81].
Schwann cells are usually transplanted by direct injection
to the site of injury, which can add to the inflammatory
process in the region. Recently, as an alternative route,
transplantation to the subarachnoid space was tried and
led to a favorable outcome [82]. The results of a phase I
human clinical trial in patients with chronic SCI will be
presented in the next annual meeting of the Congress of
Neurological Surgeons in Chicago [83].
Neural stem cells in CNS
Neural stem cells (NSCs) are present in adult and devel-
oping central nervous system of mammals and can be iso-
lated and expanded in vitro [84]. Neurosphere technique
is the most common method for isolation of NSCs. Using
this technique, stem cells have been isolated from devel-
oping spinal cord [85], cerebral cortex [86] and brain [87],
and from adult subependymal, subventricular zone of the
lateral ventricle [88,89], cerebral cortex [90] and spinal
cord [91]. Also, there was a widely held assumption that
dentate gyrus of the hippocampus contains neural stem
cells in adults. But, it has been shown recently that dentate
gyrus is a source of neural-restricted progenitors (NRPs)
and not multipotent stem cells [92]. NRPs are different
from neural stem cells as they are committed to neural lin-
eage at time of isolation. It has been shown that NSCs dif-
ferentiate to neural and glial cells both in vitro [93,94] and
in vivo [93-95]. Also, following a clonal study, it has been
reported that neural stem cells from the adult mouse brain
can contribute to the formation of chimeric embryos and
give rise to cells of all germ layers [96].
The fate of in vivo differentiation of neural stem cells
depends on the niche they have been transplanted to.
When transplanted into a neurogenic region e.g. dentate
gyrus [95,97] or subventricular zone [97], they will differ-
entiate into neurons. Transplantation into other, so
called, non-neurogenic regions, such as spinal cord [94],
will induce them to differentiate into glial cells. Although
a few studies report limited differentiation in non-neuro-
genic regions [84,85], most reports are consistent with dif-
ferentiation into glial fate. This shows the importance of
environmental cues in directing the differentiation of
NSCs. NRPs isolated from fetal spinal cord were trans-
planted into normal and injured spinal cord and differen-
tiated into neurons in normal cords. But, the injured
spinal cord niche restricted their differentiation and the
cells remained undifferentiated or partially differentiated
in this niche [98]. In an interesting study, a mixed popu-
lation of NRPs and GRPs were transplanted into the
injured spinal cord. The mixed population was provided
by either direct isolation from fetal spinal cord or pre-dif-
ferentiation of NSCs in vitro. This approach resulted in
generation of a microenvironment that led to an excellent
survival, migration out of the injury site and differentia-
tion of the cells into both neural and glial phenotypes
[99,100]. Functional improvements have been reported
after transplantation of NSCs derived from embryonic spi-
nal cord [85] and brain [101], adult brain [102] and spi-
nal cord [103], and a mixed population of NRPs and GRPs
isolated from fetal spinal cord [104].
Hematopoietic stem cells and marrow stromal cells
As hematopoietic stem cells (HSCs) and marrow stromal
cells (also known as mesenchymal stem cells) (MSCs) are
more accessible than other cells mentioned in this review,
they have attracted much attention as the potential cell
sources in management of spinal cord injury. Bone mar-
row is a rich source of these cells; although, HSCs havePage 4 of 16
(page number not for citation purposes)
Journal of NeuroEngineering and Rehabilitation 2007, 4:15 http://www.jneuroengrehab.com/content/4/1/15also been obtained from umbilical cord blood [105] and
fetal tissues [106].
Much of the evidence used to support the potential of
HSCs and MSCs to differentiate into neural and glial cells
comes from in vivo studies. Transplantation of unfrac-
tioned bone marrow has led to detection of bone marrow-
derived cells that expressed neural markers in CNS, in
both animal models [107-109] and humans [110,111]. In
a recent clinical trial [112] bone marrow cells were deliv-
ered to patients with acute and chronic SCI intravenously
or via vertebral artery. The study demonstrated the safety
of the procedure. Partial improvement in the ASIA score
and partial recovery of electrophysiological recordings of
motor and somatosensory potentials have been observed
in all subacute patients (n = 4) who received cells via ver-
tebral artery and in one out of four subacute patients who
received cells intravenously. Improvement was also found
in one out of two chronic patients who received cells via
vertebral artery. In another clinical trial unfractioned bone
marrow cells were transplanted in conjunction with the
administration of granulocyte macrophage-colony stimu-
lating factor (GM-CSF) in six complete SCI patients and
followed for 6–18 months. The procedure was safe and
led to sensory improvements immediately. Also, AIS
scores improved in 5 patients [113].
As unfractioned bone marrow is a mixture of different
progenitor cells that might show different behavior in the
same condition, more detailed studies have been per-
formed on isolated fractions of HSCs and MSCs. Deriva-
tion of cells which have been phenotypically defined as
neurons [106,114] and glial cells [105,106] has been
reported after in vitro differentiation of HSCs. But, the
point to be remembered is the fact that subsets of hemat-
opoietic stem cells express neuronal and oligodendroglial
marker genes [115,116] and this should be considered in
interpretation of results of any differentiation study.
It was reported that transplanted hematopoietic stem cells
transdifferentiate in vivo into neurons and glial cells with-
out fusion [117]. But, dissimilar results were obtained
from in vivo transdifferentiation studies. For example
Koshizuka et al [118] have shown that HSCs only differ-
entiate into glial cells not neurons. Lack of transdifferenti-
ation into neurons, which is a matter of controversy [119-
121], was also reported by Wagers et al [122] and Castro
et al [123]. A recent electrophysiological study on neuron-
like cells derived from HSCs failed to detect generation of
action potentials in these cells [124]. But, locomotor
improvement has been reported in the mice with con-
tused spinal cord after transplantation of hematopoietic
stem cells [118,125]. Also, it was shown that implantation
of HSCs into developing spinal cord lesion of chicken
embryos directs these cells to differentiate into neurons
with no apparent fusion to the host cells [126]. These
apparently disparate findings may be due to the issues
such as the employed technique, the subpopulation of the
HSCs used, and the experimental model. A phase I clinical
trial in which CD34+ cells were delivered into the injured
spinal cord via lumbar puncture technique demonstrated
feasibility and safety of the procedure after 12 weeks of
follow up [127].
The capacity of marrow stromal cells (MSCs) to differenti-
ate in vitro into cells expressing neuronal markers have
been shown in a number of studies [128,129], and the
potential of these cells to generate voltage-sensitive ionic
current was confirmed by electrophysiological recording
[130]. In vitro differentiation into glial cells was also
reported [131]. In vivo differentiation into neurons
[132,133] and glial cells [134-136] has been reported in a
number of studies. But a few studies have failed to dem-
onstrate this transdifferentiation [125,137,138]. Fusion is
another observation that needs to be considered. The
question that bone marrow cells may adopt the pheno-
type of other cells by cell fusion was raised by in vitro
observations [139,140] and tested in an in vivo model in
which fusion of marrow stromal cells with Purkinje neu-
rons was detected [141]. It has been shown that trans-
planted cells are capable not only to migrate in the injured
tissue [135,142] but also to attract host cells to the site of
transplantation [137]. Also, they form cell bridges within
the traumatic cavity [134,137]. To address the best rout of
delivery of these cells, chronic paraplegic rats received
MSCs either locally or intravenously and it was concluded
that transplantation of the cells to the spinal cord leads to
superior functional recovery [143]. Locomotor improve-
ments have been reported in most of the above studies
even in those that did not detect transdifferentiation. This
observation was attributed to secretion of cytokines and
growth factors from MSCs [138,144], which might be sub-
jected to batch-to-batch variation [138]. The point to be
considered is that in most studies locomotor function was
assessed by the Basso-Beattie-Breshnahan (BBB) test,
which is a subjective test. More objective tests such as elec-
trophysiological studies should be considered for achiev-
ing to more conclusive results. To the author's knowledge,
no peer-reviewed clinical trial using MSCs for SCI patients
has been published yet. But, a clinical trial involving
transplantation of in vitro expanded MSCs to the spinal
cord of the patients with amyotrophic lateral sclerosis
revealed that the procedure is safe and feasible [145].
Embryonic stem (ES) cells
Embryonic stem (ES) cells are pluripotent cells derived
from inner cell mass of the blastocyst, an early embryonic
stage. It has been known for many years that pluripotent
embryonic stem cells can proliferate indefinitely in vitroPage 5 of 16
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germ layers [146].
Neural stem cells derived from ES cells can lead to behav-
ioral improvement after transplantation to the site of
injury in the spinal cord [147]. It has been shown that
after prolonged in vitro expansion of ES cells-derived neu-
ral stem cells, they remain able to differentiate into neu-
rons and astrocytes both in vitro and upon transplantation
into brain [148]. Transplantation of motor neuron-com-
mitted ES cells to the injured spinal cord combined with
pharmacological inhibition of myelin-mediated axon
repulsion and provision of attractive cues within the
peripheral nerves led to extension of transplanted axons
out of the spinal cord. The axons reached the muscle,
formed neuromuscular junctions and their functionality
was confirmed by electrophysiological studies [149].
Transfection of ES cells with MASH1 gene is another strat-
egy that caused ES cells to differentiated into motor neu-
rons lacking Nogo receptor after transplantation into the
transected spinal cord of mice and led to functional
improvements confirmed by electrophysiological assess-
ment [150]. Myelination was also addressed in a number
of studies; for example, it was shown that neural cells
derived in vitro from ES cells can myelinate the demyeli-
nated rat spinal cord upon transplantation [151]. Oli-
godendrocyte-restricted progenitor cells were also derived
from ES cells and were able to enhance remyelination and
led to functional improvements after transplantation into
a rat model of acute spinal cord injury [152].
Scaffolds
As, lack of extracellular matrix at lesion site that directs
and organizes the wound healing cells is one of the mech-
anisms that interferes with regenerative process after spi-
nal cord injury, different studies have been conducted to
investigate the potential of bioscaffold grafts to promote
regeneration in the injured spinal cord, and to provide a
bridge through which the regenerating axons can be prop-
erly guided from one end of the injury to the other end.
Scaffolds were applied either alone or, to increase their
healing effects, in combination with different growth fac-
tors or cellular components.
Acellular scaffolds
Collagen
As the major constituent of extracellular matrix, collagen
supports neural cells attachment and growth [153]. Neur-
aGen™ Nerve Gide, a commercial peripheral nerve graft
made of type I collagen, received FDA clearance for mar-
keting in 2001. In spinal cord injuries, collagen has been
used to fill the gap and the present evidence shows that it
supports axonal regeneration. Collagen is a component of
inhibitory glial scar and there is some evidence that it
might inhibit nerve growth [154]. But, it has been sug-
gested that collagen is not inhibitory to axonal regenera-
tion per se and its effects depend on whether it contains
inhibitory or trophic factors (see Klapka and Müller [155]
for review). Application of cross-linked collagen and col-
lagen filaments [156,157] have been studied in animal
models of SCI. They increased regenerative activity in the
spinal cord and improved the functional disability. It was
observed that if the orientation of the grafted collagen fib-
ers was parallel to the axis of the spinal cord, they pro-
moted the growth of the regenerating axons into the graft
from both proximal and distal ends. In this model, regen-
erating axons were also observed parallel to the axis of
implant at the proximal host-implant interface. But, at the
distal interface the running regenerating axons were
entangled [156,157]. The results of implantation of a col-
lagen tube in the injured spinal cords of rats were also
promising showing that regenerating spinal axons regrow
into the ventral root through this tube [158]. It has also
been shown that impregnation of collagen with neuro-
trophin-3, increased the growth of corticospinal tract fib-
ers into the implant and led to significant recovery of
function of rats under investigation despite absence of
regrowth of these fibers into the host tissue [159]. Surgical
reconstruction of transected cat spinal cord using collagen
plus omental transposition increased regenerative activity
and led to functional recovery [160]. Functional recovery
has also been observed by collagen implantation and
omental transposition in a patient with SCI [160]. It has
been shown that inclusion of collagen, supplemented
with fibroblast growth factor-1 (FGF-1) or neurotrophin-
3 (NT-3), within the hydrogel guidance channels
improves axonal regeneration. FGF-1 increases axonal
regeneration from reticular and vestibular brainstem
motor neurons. But, NT-3 decreases the regeneration rate
of brainstem motor neurons and only increases local
axonal regeneration [154].
Alginate
Alginate is an extracellular matrix derived from the brown
seaweed from which a sponge has been developed by
cross-linking of its fibers with covalent bonds [161]. In an
in vitro study, it has been shown that when olfactory
ensheathing cells, Schwann cells and bone marrow stro-
mal cells are cultured on alginate hydrogel, they are trans-
formed into atypical cells with spherical shape and their
metabolic activities are inhibited; it has also been shown
that alginate inhibits growth of dorsal root ganglia neu-
rons [162].
But, when alginate sponge was implanted in the spinal
cord of rats, it promoted axonal elongation, and the axons
establish electrophysiologically functional projections
and lead to functional improvements [163,164]. Also,
interestingly, it was found that the axons that entered the
sponge from the rostral and caudal stumps were able toPage 6 of 16
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functional synapses with local neurons [165]. When com-
pared with collagen, alginate reduced glial scar formation
at the construct-tissue interface [161]. Also, the number of
axons entered the alginate sponge were significantly
higher than collagen [161]. In another experiment, algi-
nate and fibronectin were used to coat poly-β-hydroxybu-
tyrate (PHB) fibers obtained from bacterial cultures.
When this construct was implanted to the rats with SCI, it
increased the survival rate of rubrospinal tract axons. But,
it did not lead to ingrowth of nerve fibers into the con-
struct [166]. Recently, an alginate-based anisotropic capil-
lary hydrogel (ACH) was implanted into the cervical
spinal cord injury of rats and robustly increased the
ingrowth of longitudinally directed regenerating axons
into this implant [167].
Poly(α-hydroxy acids)
Poly(α-hydroxy acids) are synthetic biodegradable poly-
mers with excellent biocompatibility and the possibility
of changing their specifications, and especially their
mechanical properties and degradation rates, by altera-
tion of the composition and distribution of their repeat-
ing units [168]. The advantages of synthetic scaffolds over
the natural scaffolds are their lower batch-to-batch varia-
tion, more predictable and reproducible mechanical and
physical properties and higher potential for control of
materials impurities. It has been shown when the poly(D,
L-lactic-co-glycolic acid) 50:50 (PLA25GA50) is applied to
the completely transected spinal cord of rats, it demon-
strates good mechanical properties and encourages axonal
regeneration. The regenerated axons were observed pene-
trating the graft and the glial and inflammatory response
near the lesion was similar to the controls [169]. For pro-
vision of a better 3-dimensional construct, macroporous
scaffolds (foams) were made of poly(D, L-lactic acid)
(PDLLA) containing poly(ethylene oxide)-block-poly(D, L-
lactide) (PELA) copolymer (PDLLA-PELA foams). The
foams were molded into small diameter rods and 14–20
rods were assembled using acidic fibroblast growth factor
(aFGF)-containing fibrin glue and used to bridge the
transected rat spinal cord. The construct was invaded by
blood vessels and axons from proximal and distal spinal
stumps, and axonal regrowth preferentially occurred
along the main pore direction [170,171]. In another
experiment, the same foam was made with the same
diameter as rat spinal cord, treated with the neuroprotec-
tive brain-derived neurotrophic factor (BDNF), and
embedded in fibrin glue containing aFGF. Apart from eas-
ier handling, this construct possessed a good flexibility
and was able to support formation of blood vessels and
migration of astrocytes, Schwann cells, and axons. BDNF
led to the ingrowth of more regenerating axons to the
implant, mainly at the rostral part. But the implants did
not improve functional performance [172].
Synthetic hydrogels
Synthetic hydrogels, such as poly [N-2-(hydroxypropyl)
methacrylamide] (PHPMA) hydrogel (NeuroGel™) [173]
and poly(2-hydroxyethyl methacrylate-co-methyl meth-
acrylate) (PHEMA-MMA) [174], consist of crosslinked
networks of hydrophilic co-polymers that swell in water
and provide three-dimensional substrates for cell attach-
ment and growth. Their ability to retain substantial
amount of water with respect to the network density
makes them suitable for transport of small molecules.
These materials show low interfacial tension with biolog-
ical fluids and can be formulated to have the same
mechanical properties similar to the spinal cord [175-
177]. They are nonbiodegradable materials. The advan-
tage of these materials over the biodegradable materials is
that they do not expose the tissues to the intermediary
breakdown products, which may adversely affect the
regeneration process [175].
After implantation of NeuroGel into the transected cat
spinal cord, it was infiltrated by blood vessels, glial cells
and regenerating descending supraspinal axons of the
ventral funiculus and afferent fibers of the dorsal column,
and most of regenerating axons were myelinated, mainly
by Schwann cells. The regenerating axons were able to
leave the implant both rostrally and caudally. The animals
showed variable degrees of locomotor improvements
[177]. Hydrogel decreased the gliotic scar formation at the
interface between cord stump and the implant. Also, it
considerably reduced the damage to the distal cord stump
manifested by presence of more intact myelinated fibers
and reduction of myelin degradation [178]. NeuroGel was
also implanted in the post-traumatic lesion cavity in a rat
model of chronic compression-produced injury of spinal
cord. The hydrogel was invaded by blood vessels and glial
cells. Also, ingrowth of regenerating axons was observed
from the rostral stump into the NeuroGel. The axons were
associated with well-organized myelin sheets and
Schwann cells. Functional recovery was also observed
[179]. In another interesting study, the cell-adhesive
sequence Arg-Gly-Asp (RGD) of the central-binding
domain of the extracellular matrix (ECM) glycoprotein
fibronectin was incorporated into the NeuroGel (PHPMA-
RGD hydrogel). This core tripeptide sequence plays a cen-
tral role in the adhesion-mediated cell migration required
for tissue construction during development and repair.
The PHPMA-RGD hydrogel was implanted in the
transected cord of rats and led to angiogenesis and axonal
growth. It was shown that axons enter the construct from
the rostral cord and leave it into the caudal stump. The
axons were myelinated by Schwann cells, and supraspinal
axons and synaptic connections were observed in the
reconstructed cord segment. The rats showed some
degrees of functional improvements [180].Page 7 of 16
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roGel. When both NeuroGel and PHEMA were implanted
into the rat cortex, NeuroGel was invaded by various con-
nective tissue elements, but PHEMA hindered ingrowth of
connective tissue and only allowed astrocyte invasion
[181]. Unfilled PHEMA-MMA channels were used to
bridge the transected spinal cord of rats using fibrin glue.
A tissue bridge formed inside the channel between two
stumps and brainstem motor neurons regenerated
through this bridge to the distal stump. Also, the channel
limited the ingrowth of scar tissue. But, the channels did
not improve the functional recovery [174]. In another
experiment, PHEMA soaked in brain-derived neuro-
trophic factor (BDNF) solution was implanted in
hemisected rat spinal cords. BDNF did not have any effect
on the scarring and angiogenesis but, it promoted axonal
regeneration [175]. Axonal regeneration into the implant
is also improved when PHEMA-MMA channels are filled
with the matrices such as collagen, fibrin and Matrigel
[154].
Polyethylene glycol
Polyethylene glycol (PEG) is a water-soluble surfactant
polymer. Brief application of aqueous solution of this pol-
ymer to the site of injury in the spinal cord seals and
repairs cell membrane breaches, reverses the permeabili-
zation of the membrane produced by injury, inhibits pro-
duction of free radicals [182-184], and decreases oxidative
stress [185,186]. PEG was able to re-establish the anatom-
ical continuity and lead to functional recovery of severed
guinea pig spinal cord [187]. It has been shown that brief
application of PEG to the injured spinal cord of guinea
pigs reduces cystic cavitation and the extent of the injury
[188], and improves behavioral function [189,190]. But,
prolonged application can induce conduction block
[191].
Fibrin
Fibrin is derived from blood and is the major component
of clots. Fibrin functions as bridging molecule for many
types of cell-cell interactions. At the site of injury, many
cells directly bind to the fibrin via their surface receptors.
This helps localization of these cells to the site of injury
and carrying out their specialized function [192]. In the
treatment of SCI, the fibrin is usually enriched with acidic
fibroblast growth factor (aFGF) and is used in conjunction
with other modalities. Its application in combination
with poly(α-hydroxy acids) and synthetic hydrogels has
been described in the above paragraphs. When the site of
cord injury was filled with a fibrin gel, which was engi-
neered to release neurotrophin-3 after degradation by the
invading cells, vigorous cellular infiltration of the fibrin
and diminished formation of the glial scar was observed
[193]. In addition to the above applications, fibrin glue is
regularly used for stabilization of cellular bridges to the
implantation site (see below).
Matrigel
Matrigel is an extracellular matrix extracted from the
Engelbreth Holm Swarm (EHS) sarcoma and contains
laminin, fibronectin, and proteoglycans, with laminin
predominating [194]. In an in vitro study, it has been
shown that Matrigel stimulates cell proliferation and pre-
serves the typical morphological features of olfactory
ensheathing cells, Schwann cells and bone marrow stro-
mal cells in culture; and it also supports growth of dorsal
root ganglia neurons [162]. Implantation of Matrigel
alone does not increase regenerative activities in the spi-
nal cord [195]. But, Matrigel combined with vascular
endothelial growth factor (VEGF) or a replication-defec-
tive adenovirus coding for VEGF decreases retrograde
degeneration of corticospinal tract axons and increases
axonal regenerative activities in rats. Regenerating axons
growing from the rostral part of the lesion cross the
implant and can be found in the distal cord [196]. Also,
inclusion of Matrigel within hydrogel guidance channels
increases the number of regenerating axons penetrating
the construct. But, this inhibits regeneration of brainstem
motor neurons [154]. Also, it has been shown that
implantation of PAN/PVC guidance channels (see below)
containing Matrigel enriched with glial cell line-derived
neurotrophic factor (GDNF) enhances growth of regener-
ating axons into the implant [197]. Matrigel has been
used as regular scaffold for construction of bridges made
of Schwann cells and also for delivery of human adult
olfactory neuroepithelial-derived progenitors (see below).
Fibronectin
Fibronectin (Fn) is a glycoprotein found in many extracel-
lular matrices and in plasma. It is involved in cell attach-
ment and migration due to its interaction with cell surface
receptors [198]. Fibrous aggregates of plasma fibronectin
have been used to make fibronectin mats. These mats con-
tain pores oriented in a single direction [199]. The rate of
resorption of these mats can be modified by incorpora-
tion of copper and zinc ions [200]. When Fn mats were
implanted in hemisected rats spinal cords, they well inte-
grated with the spinal cord and showed little cavitation
either within or adjacent to the implant. Orientated
growth of GABAergic, cholinergic, glutamatergic,
noradrenergic axons and calcitonin gene-related peptide
(CGRP)-positive neurons occurred into the mat and axons
were myelinated by Schwann cells. Incubation of mats
with BDNF and NT-3 increased neurofilament-positive
and glutaminergic fibers. Incorporation of nerve growth
factor into the mats increased the number of CGRP-posi-
tive neurons. But, there was little axonal outgrowth from
the mats into the host spinal cord [199]. After implanta-
tion, Fn mats are vascularized and infiltrated by macro-Page 8 of 16
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axons, oligodendrocytes and their precursors and astro-
cytes. Laminin deposition is also observed in the mats
[201]. This failure of outgrowth of axons from the mat to
the surrounding tissue was attributed to the astrocytosis
and glial scar formation around the implant. The attempts
to decrease this astrocytosis by incubation of mats with
antibodies to transforming growth factor β (TGFβ) not
only did not solve the problem, but also exacerbated the
extent of secondary damage [202].
In an in vitro study, it has been shown that combination
of fibronectin with alginate hydrogel supports olfactory
ensheathing cells proliferation. But, the proliferation rate
was significantly lower than what was observed on
Matrigel [162]. Incorporation of the central binding
domain of fibronectin i.e. Arg-Gly-Asp (RGD) to the Neu-
roGel (PHPMA-RGD hydrogel) has been performed in an
interesting study to enhance its cell adhesion and guid-
ance capacity. Implantation of this construct into the spi-
nal cord of rats led to angiogenesis and axonal growth
into the implant (see above) [180]. Fibronectin has also
been used to make fibronectin cables with parallel fibril
alignment. It has been shown that these cables support
Schwann cells growth in vitro and these cells align with the
axis of the fibrils [198].
Agarose
Agarose is a polysaccharide derived from seaweed.
Recently, a freeze-dried agarose scaffold with uniaxial lin-
ear pores extending through its full length was manufac-
tured and its biocompatibility and ability to function as a
depot for growth factors was confirmed by in vitro studies
[203]. These scaffolds retain their microstructure without
the use of chemical cross-linkers. Also, they can retain
their guidance capabilities within the spinal cord for at
least 1 month. Implantation of BDNF-incorporated scaf-
folds in a rat model of spinal cord injury, led to organized
and linear axonal growth into the agarose. The implant
was also penetrated with Schwann cells, blood vessels and
macrophages. Agarose did not evoke fibrous tissue encap-
sulation in host tissue [204].
Another recent approach is to use in situ gelling agarose
hydrogel. An irregular, dorsal over-hemisection spinal
cord defect in adult rats was filled with agarose solution
embedded with BDNF-loaded microtubules and was
cooled until gelation. This allowed the gel to conformally
fill the defect by adopting its shape and minimized the
gap between tissue and scaffold. The implant was pene-
trated by axons only in the presence of BDNF. But, no out-
growth of axons from the implant to the host distal cord
was observed. The other observed effect was reduction of
the intensity of reactive astrocytosis and deposition of




Matrigel has been used as a scaffold for in vivo delivery of
Schwann cells in several experiments. Purified Schwann
cells were mixed with Matrigel and inserted in semiper-
meable non-degradable 60/40 polyacrylonitrile/polyvi-
nylchloride (PAN/PVC) copolymer guidance channels.
This construct was used to bridge a transected rat spinal
cord. Histological studies demonstrated penetration of
the implanted bridge by myelinated axons, blood vessels,
macrophages and fibroblasts. When the models under-
went electrophysiological studies, stimulus-evoked cord
potentials were clearly identified in a few models, show-
ing functionality of regenerating axons [70]. When this
model was combined by infusion of BDNF or NT-3 to the
distal cord stump, axonal growth from the implant into
the distal host spinal cord stump was effectively promoted
for several cord segments. In the absence of BDNF or NT-
3 only a few axons were able to enter the distal stump
[78]. In another experiment, instead of infusion of BDNF
distal to the implant, the BDNF was added to the SC/
Matrigel cable inside the PAN/PVC guidance channels.
This approach led to increased growth of regenerating
axons into the construct as well. Also, GDNF decreased
the extent of reactive gliosis and cystic cavitation at the
graft-host interface [197]. Recently, a combination of SC/
Matrigel cable inside PAN/PVC channels with implanta-
tion of olfactory ensheathing cells (OECs) in the distal
and proximal cord stumps and infusion of chondroitinase
ABC to the SC bridge/host spinal cord interface was stud-
ied in a rat model of spinal cord transection [79]. OECs
were implanted to enable regenerating axons to exit the
SC/Matrigel bridge, and chondroitinase ABC was used to
reduce the axonal regeneration inhibitory effect of chon-
droitin sulfate proteoglycan (CSPG) in the glial scar. This
combined implantation therapy significantly increased
the number of myelinated axons and serotonergic fibers
in the bridge, and the latter grow in the distal cord stump.
Also, significant functional improvement was observed.
In another experiment carried out by implantation of SC/
Matrigel cables contained in biodegradable scaffolds
made of poly(alpha-hydroxy acids) (PHAs) such as
poly(D, L-lactic acid) (PLA50) or high molecular weight
poly(L-lactic acid) mixed with 10% poly(L-lactic acid) oli-
gomers (PLA100/10), the intervention led to axonal
ingrowth into the implant but, it was not as effective as the
PAN/PVC experiment [206]. In another experiment,
Matrigel was used for seeding of Schwann cells derived
from human bone marrow stromal cells in an ultra-filtra-
tion membrane (Millipore) tube. This construct pro-
moted axonal regeneration into the bridge and resulted in
recovery of hind limb function in rats [207].Page 9 of 16
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tory neuroepithelial-derived progenitors with Matrigel
was studied in a rat model of hemisected spinal cord
injury. This approach has led to regeneration of rubrospi-
nal neurons through the transplant within the white mat-
ter for several segments caudal to the graft so that a few
rubrospinal axons terminated in gray matter close to
motor neurons. Improvements in functional recovery
were also observed in this experiment [195].
Collagen construct
The ease of manipulation of collagen into various shapes
allows precise application of the cells to the injured site.
Cortical neonatal rat astrocytes were embedded in colla-
gen type I gel and transplanted to the hemisected rat spi-
nal cords. Collagen prevented migration of astrocytes into
the host tissue, which was believed to be an advantage, as
their presence could attract more regenerating axons into
the implant. This approach has resulted in significant
increase of number of ingrowing neurofilament-positive
fibers (including corticospinal axons) into the implant.
But, the fibers did not reenter the host tissue. Modest tem-
porary improvements of locomotor recovery were
observed in this study which was hypothetically attributed
to the factors secreted from transplanted astrocytes [208].
Alginate constructs
Recently, it has been shown that adult neural progenitor
cells harvested from rats cervical spine can be mounted on
an alginate-based anisotropic capillary hydrogel (ACH)
and this construct supports axonal regeneration in vitro
[167].
In another experiment, neurospheres prepared from fetal
rat hippocampus were injected into the alginate sponge,
and implanted in the injured spinal cord of rats. Alginate
increased the survival of neurospheres after transplanta-
tion and supported their migration, differentiation and
integration to the host spinal cord [209]. Microencapsula-
tion of fibroblasts producing brain-derived neurotrophic
factor (BDNF) in alginate-poly-L-ornithine is another
method for application of alginate in treatment of SCI.
Microcapsules protect fibroblasts from the host immune
response and eliminate the need for immunosuppressive
therapy. These constructs were injected to the spinal cord
in a rat model of SCI and promoted growth of regenerat-
ing axons into the cellular matrix that developed between
the capsules. They also led to improvement of the func-
tion of the affected limbs [210,211]. In another study,
neonatal Schwann cells were seeded on alginate and
fibronectin-coated poly-β-hydroxybutyrate (PHB) fibers
and supported ingrowth of regenerating axons, which
extended along the entire length of the graft [166].
Fibrin constructs
Fibrin has been used to enhance the effects of cell-scaffold
constructs. In most instances, fibrin is used with acidic
fibroblast growth factor (aFGF). It has been shown that
basic fibroblast growth factor (bFGF) is not efficient in
this setting [212]. Fibrin containing aFGF has been
applied to both ends of Schwann cells/Matrigel cables in
PAN/PVC guidance channels. They increased sprouting of
corticospinal tracts in rats; and the axons that entered the
graft left the implant and entered the host spinal cord
from the opposite end [213]. Preparation of a mixture of
cell suspension and fibrinogen for direct transplantation
to the injured spinal cord is another approach for applica-
tion of fibrin in clotted form. But, such a preparation
made of olfactory ensheathing cells (OECs) did not prove
to be effective in a rat model of SCI [45]. Fibrin clots have
been used for delivery of Schwann cells as well. SC/fibrin
clot has been inserted in PAN/PVC guidance channels and
were used to bridge a transected rat spinal cords. This was
combined by transduction of caudal spinal cord stump
cells with adeno-associated viral (AAV) vectors encoding
for brain-derived neurotrophic factor (BDNF) or neuro-
trophin-3 (AAV-NT-3). Histological sections have shown
the ingrowth of axons from the rostral stump into the
bridge, but the axons did not leave the bridge. On the
other hand, the transduced neurons in the caudal stump
extended their processes into the implant. This combined
treatment led to significant improvement of hind limb
function in treated animals [214].
Poly(α-hydroxy acids)-construct
A two-component scaffold was made of a blend of 50:50
poly(lactic-co-glycolic acid) (PLGA) (75%) and a block
copolymer of poly(lactic-co-glycolic acid)-polylysine
(25%). The scaffold's inner portion emulated the gray
matter via a porous polymer layer and its outer portion
emulated the white matter with long, axially oriented
pores for axonal guidance and radial porosity to allow
fluid transport while inhibiting ingrowth of scar tissue.
The inner layer was seeded with a clonal multipotent neu-
ral precursor cell line originally derived from the external
germinal layer of neonatal mouse cerebellum. Implanta-
tion of this construct into the hemisection adult rat model
of spinal cord injury led to a long-term functional
improvement accompanied by reduction of epidural and
glial scar formation and growing of regenerating corticos-
pinal tract fibers through the construct, from the injury
epicenter to the caudal cord [215].
Conclusion
The complicated pathophysiology of spinal cord injury
and its consequent disability had made the pace of thera-
peutic interventions in this field very slow for many years.
But, in the last decade, the rapid progress that has been
made in the field of tissue engineering as the result ofPage 10 of 16
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opened up the way for new therapeutic strategies. These
new strategies have shown promising results and the sci-
entists are hoped to cure the patients with spinal cord
injury before long.
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